Claims for Patent: 9,107,912

Summary for Patent: 9,107,912

Title:	Methods for concomitant treatment of theophylline and febuxostat
Abstract:	The present disclosure relates to a method of treating hyperuricemia in a patient that also suffers from a second disease state requiring treatment with theophylline, wherein the patient receives concomitant treatment with a xanthine oxidoreductase inhibitor and theophylline without resulting in theophylline toxicity to the patient and without substantial adjustments to the manufacturer's recommended dosage of theophylline.
Inventor(s):	Gunawardhana; Lhanoo (Pleasant Prairie, WI), Tsai; Max (Highland Park, IL), Naik; Himanshu (Evanston, IL)
Assignee:	Takeda Pharmaceuticals U.S.A., Inc. (Deerfield, IL)
Application Number:	13/227,828
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,107,912
Patent Claims:	1. A method of treating hyperuricemia in a patient in need of treatment thereof, the method comprising the steps of: administering to a patient suffering from hyperuricemia and at least one second disease state, a therapeutically effective amount of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, wherein the subject is also receiving concomitant administration of theophylline to treat the at least one second disease state, and further wherein (i) the administration of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid or a pharmaceutically acceptable salt thereof, to the patient does not result in theophylline toxicity to the patient; and (ii) administration of the theophylline is in an amount ranging from about 90% to about 110% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. 2. The method of claim 1, wherein the second disease state is asthma. 3. The method of claim 1, wherein the patient is further suffering from at least one third disease state, wherein the third disease is gout. 4. The method of claim 1, wherein the theophylline dosage amount ranges from about 95% to about 105% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. 5. The method of claim 1, wherein the theophylline dosage amount ranges from about 99% to about 101% of a manufacturer's recommended theophylline dosage amount in the absence of administration of at least one xanthine oxidoreductase inhibitor. 6. The method of claim 1, wherein the patient suffering from hyperuricemia and the at least one second disease state is previously administered theophylline prior to initiation of treatment with 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid.